Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, an investigational targeted protein degrader, versus docetaxel in patients with KRAS G12D‑mutated locally advanced (unresectable) or metastatic non‑small cell lung cancer (NSCLC) whose disease progressed on or after platinum‑based chemotherapy and checkpoint inhibitor (CPI) therapy.
Phase 3 Trial Overview
| Item | Detail |
|---|---|
| Sponsor | Astellas Pharma Inc. (TYO: 4503) |
| Study Design | Phase 3, multinational; setidegrasib vs. docetaxel (active comparator) |
| Population | KRAS G12D‑mutated locally advanced (unresectable) or metastatic NSCLC |
| Prior Therapy | Progression on or after initial platinum‑based chemotherapy and checkpoint inhibitor (CPI) |
| Dual Primary Endpoints | Progression‑free survival (PFS) by blinded independent central review; overall survival (OS) |
| Planned Enrollment | Approximately 356 patients across multiple countries |
| Status / Milestone | First patient dosed – 24 Sep 2026 |
Drug Profile & Mechanism of Action
- Molecule: Setidegrasib – investigational, orally administered modality class described by the sponsor as a targeted protein degrader.
- Target: The KRAS G12D mutant protein – a disease‑driving oncoprotein.
- Mechanism: Rather than merely inhibiting signaling, setidegrasib is designed to degrade and eliminate the KRAS G12D protein itself, attacking the driver at the protein‑level source.
- Prior Clinical Evidence: Early‑stage data have demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12D‑mutated solid tumors; detailed response rates and cohort sizes were not disclosed in the announcement.
- Development Rationale: The Phase 3 program builds directly on that early evidence, advancing the degrader into a head‑to‑head registrational‑style comparison against docetaxel, the chemotherapy standard of care in the post‑platinum, post‑CPI setting.
Clinical Context – KRAS G12D in NSCLC
- Mutation Background: KRAS is among the most frequently mutated oncogenes in NSCLC; the G12D substitution is a leading subtype. Unlike KRAS G12C, for which covalent inhibitors are approved, G12D has historically resisted direct pharmacological targeting – an “undruggable” niche long considered out of reach.
- Standard of Care Gap: Patients progressing after platinum chemotherapy and checkpoint inhibitors are typically managed with single‑agent chemotherapy such as docetaxel, which offers limited efficacy and substantial toxicity – a clear unmet need for mutation‑targeted options.
- Endpoint Rigor: The use of dual primary endpoints (PFS by BICR and OS) signals a design intended to support potential regulatory filings in major markets, with survival data providing the highest bar of clinical benefit.
Market Impact & Outlook
- Modality Validation: The initiation of a Phase 3 degrader trial marks a milestone for targeted protein degradation, moving the modality from preclinical promise toward late‑stage clinical proof in oncology.
- Precision‑Oncology Positioning: Success would establish biomarker‑selected (KRAS G12D) patient targeting in lung cancer, extending the precision‑medicine playbook pioneered in G12C disease to a new mutation class.
- Competitive Landscape: Setidegrasib would compete directly with docetaxel in a defined second‑line‑plus population and, potentially, with other emerging G12D‑directed programs in clinical development.
- Commercial Stakes: The approximately 356‑patient multinational design balances statistical power for dual survival endpoints with feasible enrollment in a molecularly screened population; readout timing was not disclosed.
- Next Steps: Site activation and patient screening across multiple countries; further details on dosing schedule, randomization ratio, and regional regulatory strategies were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, enrollment timelines, efficacy and safety outcomes, regulatory filings, and commercial expectations for setidegrasib. Actual results may differ materially due to risks inherent in late‑stage oncology development, including endpoint failure, unexpected toxicity, enrollment shortfalls, and competitive and regulatory dynamics.-Fineline Info & Tech
